ReviewPPAR research2016
Current Advances in the Biochemical and Physiological Aspects of the Treatment of Type 2 Diabetes Mellitus with Thiazolidinediones.
Review in PPAR research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 53 citations in OpenAlex.
- Evaluation of 3',4'-Di-Biomolecules · 2026Article
- Targeted therapeutic strategies as alternative and sustainable treatment options for obesity-induced steatohepatitis.Reviews in endocrine & metabolic disorders · 2025Review
- Drawbacks of Olanzapine Therapy: An Emphasis on Its Metabolic Effects and Discontinuation.Journal of clinical medicine · 2025Review
- Sustainable Photocatalytic Synthesis of Glitazones via Riboflavin Tetraacetate.The Journal of organic chemistry · 2025Article
- Article
- Dose-response technique combined with stable isotope tracing for drug metabolite profiling by using high-resolution mass spectrometry.Frontiers in pharmacology · 2023Article
- Natural Compound 3β,7β,25-trihydroxycucurbita-5,23(E)-dien-19-al fromMolecules (Basel, Switzerland) · 2021Article
- Commonly Prescribed and Over-the-Counter Drugs as Secondary Causes of Osteoporosis-Part One.Integrative medicine (Encinitas, Calif.) · 2021Article
- Drugs Affecting Body Weight, Body Fat Distribution, and Metabolic Function-Mechanisms and Possible Therapeutic or Preventive Measures: an Update.Current obesity reports · 2021Review
- Article
- Review
- Current molecular aspects in the development and treatment of diabetes.Journal of physiology and biochemistry · 2020Review
- Structure-Activity Relationship Study of Acyclic Terpenes in Blood Glucose Levels: Potential α-Glucosidase and Sodium Glucose Cotransporter (SGLT-1) Inhibitors.Molecules (Basel, Switzerland) · 2019Article
- GVS-12 attenuates non-alcoholic steatohepatitis by suppressing inflammatory responsesRSC advances · 2019Article
- Trans-repression of NFκB pathway mediated by PPARγ improves vascular endothelium insulin resistance.Journal of cellular and molecular medicine · 2019Article
- PPAR-PPAR research · 2019Article
- Insulin Mimetic Properties of Extracts Prepared fromMolecules (Basel, Switzerland) · 2018Article
- An In Ovo Model for Testing Insulin-mimetic Compounds.Journal of visualized experiments : JoVE · 2018Article
- PPAR-γ Agonists As Antineoplastic Agents in Cancers with Dysregulated IGF Axis.Frontiers in endocrinology · 2017Review
- Gluc-HET, a complementary chick embryo model for the characterization of antidiabetic compounds.PloS one · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present review summarizes the current advances in the biochemical and physiological aspects in the treatment of type 2 diabetes mellitus (DM2) with thiazolidinediones (TZDs). DM2 is a metabolic disorder characterized by hyperglycemia, triggering the abnormal activation of physiological pathways such as glucose autooxidation, polyol's pathway, formation of advance glycation end (AGE) products, and glycolysis, leading to the overproduction of reactive oxygen species (ROS) and proinflammatory cytokines, which are responsible for the micro- and macrovascular complications of the disease. The treatment of DM2 has been directed toward the reduction of hyperglycemia using different drugs such as insulin sensitizers, as the case of TZDs, which are able to lower blood glucose levels and circulating triglycerides by binding to the nuclear peroxisome proliferator-activated receptor gamma (PPARγ) as full agonists. When TZDs interact with PPARγ, the receptor regulates the transcription of different genes involved in glucose homeostasis, insulin resistance, and adipogenesis. However, TZDs exhibit some adverse effects such as fluid retention, weight gain, hepatotoxicity, plasma-volume expansion, hemodilution, edema, bone fractures, and congestive heart failure, which limits their use in DM2 patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.